[alkonaut]

Exaxtly this. Are the inputs available and we can spend just a few tens of billions on building gigafactories to make this process parallel and controlled? Then it’s like making microchips from silicon or gold from ore. Terrible yield but cheap inputs and a scalable process.

If the inputs are expensive or the process can’t scale (to a billion doses in 12 months, say) then that’s worrying and perhaps indicates this isn’t a good candidate vaccine.

[alkonaut]

Edit: remdesivir is a therapeutic, not a vaccine, so it is useful in much smaller quantities than a vaccine.